First-in-human treatment for cancer using a drug injected into tumors
Treatments studied
Part of Cancer, Digestive system, Lungs & breathing, Skin clinical trials.
This Phase 1 trial tests PeptiCRAd-1, a treatment injected into a tumor, to see how safe it is and whether it can shrink cancers. It studies people whose cancer has come back or can’t be treated with standard options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old and can sign informed consent
- You have one of these cancers: melanoma, TNBC, non-squamous lung cancer, synovial/myxoid sarcoma, osteosarcoma, or certain colorectal/sarcomas with NY-ESO-1 or MAGE-A3
- Your cancer has measurable disease and a spot the team can biopsy and inject
- You are well enough to participate (ECOG/WHO performance status 0–1) and your blood work and organ tests (liver/kidney) are within required ranges
- You can use cancer treatment you may already be on (including certain checkpoint inhibitors) with required timing, and you meet pregnancy/contraception rules if relevant
- You must not have certain recent treatments or medical issues, like live-virus vaccines, active infections needing medication, or untreated brain metastases with symptoms
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests a medicine injected directly into a tumor, alone or with pembrolizumab (an immune-therapy drug given through a vein). It is for people with advanced or metastatic solid cancers that have grown despite standard treatments, aiming to improve tumor control.
This early-phase study tests NM1F (an anti-PVRIG antibody) in people with advanced solid tumors to see if it’s safe and whether it may work. It also includes pembrolizumab (a PD-1 “checkpoint” medicine), aiming to boost the immune system against the cancer.
This Phase 1 trial tests CRX100 (a new cancer medicine) alone and with pembrolizumab (an immune checkpoint drug) in people with advanced solid tumors. It’s mainly designed to check safety and side effects, and to see whether tumors respond, potentially helping people whose cancer has come back or stopped responding to standard treatment.
This early-phase trial tests how well a new drug (BMS-986340) works alone and combined with other treatments in people with advanced solid tumors that have progressed despite standard care. It also studies tumor samples to look for biomarkers that may predict who benefits.
This Phase 1/2 trial tests T3P, a new treatment given directly into reachable solid tumors, to see if it is safe and can help shrink tumors. It is for adults with advanced cancers when no curative treatment is available.
This early-stage trial tests a new drug that combines a peptide with genetic material (siRNA) designed to help your immune system fight advanced cancers that haven't responded to standard treatments. Researchers want to see if it's safe and whether it can shrink tumors.
Hear when a new Melanoma (Skin) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.